PubMed Health⌕ Search

Biomedical subjects

T Arita

Publications and source records attributed to T Arita.

At least 199 records · Page 11Linked to original sources

Hepatic parenchymal changes after ethanol injection in rabbits: correlation of conventional and dynamic MR imaging with pathologic findings.

The purpose of this study is to clarify the changes of peripheral normal liver parenchyma before and after ethanol injection, with respect to MR appearances and pathologic findings and, in so doing, to clinically evaluate the therapeutic effectiveness of percutaneous ethanol injection (PEI) therapy. The normal liver in 12 rabbits was injected with ethanol. We performed conventional and dynamic MR imaging and prepared the histopathologic specimens 1 week (group 1), 2 weeks (group 2), and 1 month (group 3) after ethanol injection. On conventional MR images, coagulative necrosis in the normal liver was demonstrated as an area of low signal intensity on T1-weighted images and high signal intensity on T2-weighted images in all groups. On dynamic MR images, contrast enhancement in the coagulative necrosis was not seen in groups 1 and 2; however, gradual and concentric enhancement was seen in the direction of the central necrotic portion from early-to-delayed phase image in group 3. Although signal intensity of the coagulative necrotic area in the normal liver after ethanol injection may mimic that of untreated or viable hepatocellular carcinoma (HCC) when clinically encountered on conventional MR images, coagulative necrosis of the normal liver parenchyma will be discriminated from viable HCC by using dynamic MR imaging.

Animals↗

Fan-shaped hepatic parenchymal damage after ethanol injection therapy for hepatocellular carcinoma: MRI appearances.

BACKGROUND: T1- and T2-weighted magnetic resonance (MR) images frequently show fan-shaped areas of hypo- or hyperintensity in the hepatic parenchyma adjacent to a treated hepatocellular carcinoma after percutaneous ethanol injection (PEI) therapy. These areas correspond to abnormal contrast enhancement on serial dynamic MR images. The purpose of the present study was to describe the location, appearance, and frequency of these abnormalities because it is important to understand these entities for the correct assessment of therapeutic efficacy. METHODS: MR imaging including a multisection dynamic study was performed in 20 consecutive patients with hepatocellular carcinoma treated with PEI therapy. We retrospectively evaluated the presence of fan-shaped hypointensities adjacent to treated tumors in the liver parenchyma on T1-weighted images and hyperintensities on T2-weighted images and corresponding fan-shaped contrast enhancement on both arterial-dominant and delayed-phase dynamic MR images. We review the location, appearance, and frequency of these findings, and we discuss the possible causes on the basis of pathologic examinations. RESULTS: Seven (35%) of the 20 patients showed fan-shaped hyperintense areas adjacent to the treated tumors on T2-weighted images. These areas showed isointensity in five patients and hypointensity in two patients on T1-weighted images. Of these seven patients, one (14%) underwent the MR imaging within 1 month after the completion of PEI therapy, and six (86%) had it 2-9 months after the completion of PEI therapy (mean = 6 months). In all seven patients, fan-shaped hyperperfusion abnormalities corresponding to these areas of hyperintensity on T2-weighted images were seen on both arterial-dominant and delayed-phase dynamic MR images. Pathologically, the coagulative necrosis of the hepatocytes with sinusoidal dilatation and the restoration by the development of fibrous tissue were seen in these fan-shaped areas. CONCLUSION: The fan-shaped areas of abnormal intensity on T1- and T2-weighted images and contrast enhancement on dynamic MR images seem to be attributable to pathologic changes in the normal liver parenchyma induced by the toxic reaction of ethanol. Awareness of the occurrence of such abnormalities in the peripheral liver parenchyma adjacent to the treated tumor is important for the correct assessment of therapeutic efficacy.

Carcinoma, Hepatocellular↗

Hepatic perfusion abnormalities in acute pancreatitis: CT appearance and clinical importance.

BACKGROUND: The purpose of the present study was to describe the computed tomography (CT) appearances of transient hepatic attenuation differences (THADs) in patients with acute pancreatitis and to discuss the mechanism of THAD. METHODS: Two-phase dynamic CT images of 28 patients with acute pancreatitis were reviewed. Among them, THAD was seen in nine patients. All patients underwent ultrasonography, and four patients with THAD underwent surgery. RESULTS: Three types of THAD (THAD adjacent to the gallbladder in five of 28 patients, THAD with left lobar distribution in three of 28, wedge-shaped THAD in one of 28) were seen on the two-phase dynamic CT scans of patients with acute pancreatitis. In five patients, THAD disappeared when acute pancreatitis had subsided. CONCLUSIONS: THAD in acute pancreatitis is probably caused by increased arterial blood flow attributable to the inflamed lobe of the liver or the inflamed gallbladder. THAD in acute pancreatitis should not be confused with primary liver abnormalities.

Acute Disease↗

Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance.

The effects of long-term monotherapy with doxazosin, an alpha 1-blocker, or placebo on blood pressure (BP), glucose tolerance, and serum lipid levels were investigated prospectively in 43 hypertensive patients with impaired glucose tolerance. The levels of plasma glucose, serum lipids, fructosamine, and glycated hemoglobin A1c (Hb A1c) were determined before and during long-term (mean treatment period, 6.7 months) therapy with doxazosin (n = 23) or placebo (n = 20). A 75-g oral glucose tolerance test was performed before and during therapy. Significant decreases in both systolic and diastolic BP were maintained during doxazosin therapy; BP did not change in the placebo group. Neither fasting nor post-glucose-load venous plasma glucose levels were altered, and there was no significant change in the insulinogenic index in either group. Glucose intolerance was slightly improved with significant reductions in Hb A1c and fructosamine levels during doxazosin therapy. Serum total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol levels were significantly decreased, and high-density lipoprotein cholesterol levels were significantly increased in patients treated with doxazosin. Moreover, TC, LDL cholesterol, and apolipoprotein B levels were significantly decreased in patients with hypercholesterolemia (TC > or = 5.69 mmol/L). In contrast, there were no significant changes in Hb A1c, fructosamine, and lipid levels in the placebo group. These results suggest that long-term doxazosin therapy may improve glucose and lipid metabolism in hypertensive patients. Doxazosin appears useful as an antihypertensive agent for hypertensive patients with either impaired glucose metabolism or dyslipidemia.

Antihypertensive Agents↗